Optimer Continues Dificid Push In Hospitals With Discount Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
The antibiotic drug developer has been actively marketing its drug since it was approved last year, but it makes a more concerted effort to address issues of costs in hospitals, it said during at analyst day.
You may also be interested in...
Optimer Is Up For Sale And Could Attract Hospital-Focused Suitors
The antibiotic company announced it is reviewing strategic options and that CEO Pedro Lichtinger has been replaced by Chairman Henry McKinnell. Hospital-based companies looking to beef up their portfolios with a commercial asset could drive a competitive process.
Antibiotic Market Snapshot: In Exchange For Higher Prices, More Value
Drug developers face enormous regulatory and commercial hurdles in the antibiotics market, but industry is looking to challenge the current business model with new premium-priced drugs that deliver compelling pharmaco-economic benefits over generics.
Optimer’s Dificid Gets Medicare Payment “Add-On” For Hospital Patients
In a rare application of its Medicare “new technology add-on payments” policy to drugs, the Centers for Medicare and Medicaid Services announced it will supplement reimbursement to hospitals for the oral antibiotic Deficid and methotrexate toxicity antidote Voraxaze.